48 results about "Pharmacological therapy" patented technology

The present application relates to the field of medicinal chemistry and pharmacotherapy, and in particular to a class of bazedoxifene and its preparation method and application. The bazedoxifene derivative is used for gp130 small molecule inhibitor, the compound is a compound shown in formula (I), or a pharmaceutically acceptable salt or ester thereof, and relates to the application of tumor-related activity and the like, in particular the application in preparing drugs for preventing and / or treating diseases related to tumors, especially colorectal cancer.

FIELD: neurology; psychiatry.SUBSTANCE: used as a non-pharmacological therapy for autism spectrum disorders in children. The method includes a set of procedures: interval hypoxic-hyperoxic training (HHT), hyperbaric oxygenation and ozone therapy. HHT consists of alternating inhalations of a hypoxic mixture with an oxygen content of 9 to 16 vol.% and a hyperoxic mixture with an oxygen content of 32 to 40 vol.% for a total duration of 45-50 minutes under the control of cardiovascular system parameters. Hyperbaric oxygenation is performed in a pressure chamber under a pressure of 1.3 atmospheres of 100% oxygen mixture, flow of 10 liters per minute, for 45 minutes using a mask. Ozone therapy is performed by rectal insufflation with an ozone-oxygen mixture with an ozone concentration of 85 μg / ml in a volume of 20–30 ml or by intravenous administration of a physiological solution enriched with ozone with an ozone concentration of 85 μg / ml at a rate of 200 ml per 100 ml of physiological solution. The procedures are carried out daily for 12 days.EFFECT: method is effective and has a positive impact on the patient’s condition.1 cl, 1 dwg, 3 ex

The invention discloses an antibody specifically binding to CD48-1 protein or an antigen binding fragment thereof and application thereof, and belongs to the technical field of biological medicine. The invention further discloses application of the antigen binding fragment specifically binding to the CD48-1 protein, the antibody, polynucleotide, an expression vector, a host cell and the conjugate. The invention also discloses a pharmaceutical composition which comprises one of the antigen binding fragment specifically binding to the CD48-1 protein, an antibody, polynucleotide, an expression vector, a host cell and a conjugate. The antibody or the antigen binding fragment thereof has the beneficial effects that immunological rejection caused by species difference does not exist, and the antibody or the antigen binding fragment thereof has specific binding performance to human CD48-1 full-length protein, can be used for detecting the CD48-1 protein and diagnosing diseases related to the CD48-1 protein, can be used for preparing drugs specifically binding to the CD48-1 protein, and can be used for preparing the CD48-1 protein. The CD48-1 protein related diseases can be treated or prevented, and the CD48-1 protein has a wide application prospect.

The present invention provides an effective pharmacological therapy for pathological repetitive behaviours.

The invention discloses an active polypeptide for promoting healing of oral ulcer and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the active polypeptide NPTX3 capable of promoting healing of the oral ulcer is DLKPIAEDIPSLEK. An in-vitro experiment result shows that the polypeptide NPTX3 can remarkably promote the scratch closure of the human immortalized keratinocytes at the concentration as low as 500 pM. Transwell migration experiments further prove that the polypeptide NPTX3 can obviously enhance the migration ability of HaCaT cells at the concentrations of 1nM and 10nM, which prompts that the polypeptide NPTX3 may accelerate wound repair by promoting epithelial cell migration. In an SD (Sprague Dawley) rat oral ulcer model, the ulcer healing rate can be obviously improved by locally applying the polypeptide NPTX3 (1 nM, 10 nM). The polypeptide NPTX3 provided by the invention shows excellent activity of promoting cell migration and tissue repair at an extremely low dose, has the advantages of low effective dose, strong biological activity, high safety and the like, and provides an efficient and mild new choice for drug treatment of oral ulcer.

Compositions and methods relating to a pharmacological therapy for a human genetic disease, specifically mitochondrial DNA depletion-deletions syndromes, and more specifically, those related to mutations in the GUK1 gene. The pharmacological therapy involves the administration of deoxyguanosine (dG), a purine nucleoside phosphorylase (PNP) inhibitor, including but not limited to forodesine, or both.

The application discloses a lenvatinib-polyethylene glycol coupling compound and a preparation method and application thereof. The lenvatinib-polyethylene glycol coupling compound has a structure as shown in the formula (I): in the formula (I), n is greater than or equal to 2. The application further provides a nano preparation containing vinpocetine and the lenvatinib-polyethylene glycol coupling compound and used for manufacturing drugs, which can be applied to tumor treatment, effectively improves the limitation of a single drug treatment method on tumor inhibition, and shows a positive application potential in the tumor treatment field.

Provided is a pharmaceutically acceptable formulation comprising a taxane and an acid-activated 2-hydroxypropyl-β-cyclodextrin (CD). Also provided is a method of treating a patient with a taxane. The method comprises infusing the above formulation into the patient. Additionally provided is a method of preparing the above formulation. Further provided is an infusion bag comprising the above formulation.

The application belongs to the field of biomedical engineering, and discloses a human live mucosa organoid and a construction method and application thereof. The construction of the organoid comprises the following steps: preparing a cell gel compound, filling the cell gel compound into a support, implanting the support into a nude mouse subcutaneously after gelation, and obtaining the human live mucosa organoid after culturing for 1-3 weeks. The application also discloses the application of the organoid in disease research or drug screening. The application constructs a sustainable in-vivo biomimetic air-mucosa gas-liquid interface, realizes the transition of mucosa from an "ex-vivo static model" to an "in-vivo dynamic live system", and realizes the comprehensive evaluation of the curative effect of anti-infection drugs from three dimensions of pathogenic bacteria elimination, inflammation reaction regulation and immune cell recruitment inhibition in application, thereby breaking through the limitation of traditional models that can only evaluate the in-vitro bacteriostatic activity and being more consistent with the actual effect of clinical drug treatment.

The invention belongs to the technical field of biological medicines, and relates to application of an HIF-1alpha inhibitor in preparation of a product for inducing transformation of astrocytes from a pro-inflammatory type to an anti-inflammatory type. The invention reveals that activation of an HIF-1 signal channel is an important mechanism for driving neuroinflammatory response and pro-inflammatory A1 type astrocyte formation, and inhibition of HIF-1 activation can effectively promote generation of neuroprotective A2 type astrocytes. By applying the HIF-1alpha small-molecule inhibitor KC7F2 to astrocytes, HIF-1alpha activation is blocked, and the astrocytes are promoted to be converted from a proinflammatory A1 phenotype to an anti-inflammatory A2 phenotype, so that inflammatory response is inhibited, neurotoxicity is reduced, and a neuron microenvironment is improved. The invention provides a novel intervention strategy based on HIF-1alpha signal regulation and control, and a novel theoretical basis and a novel potential drug treatment scheme are provided for treatment of nervous system injury and related neurodegenerative diseases.

The invention discloses application of circKIAA1617 serving as an ER < + > breast cancer treatment target and a prognostic marker. According to the invention, circKIAA1617 is found to be used as an ER + breast cancer diagnosis biomarker and a drug treatment target for the first time; experiments prove that in-vitro and in-vivo proliferation of ER + breast cancer cells can be inhibited by interfering expression of circKIAA1617, and proliferation and stemness progress of ER + breast cancer can be promoted by circKIAA1617; the circKIAA1617 can be used for promoting lipophagy of ER < + > breast cancer cells; therefore, the circKIAA1617 plays a role in promoting the cancer in the development of the ER + breast cancer.

Provided is a medicament for treating or preventing cerebral hemorrhage, which contains, as an active ingredient, a compound of the following formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof.

The invention belongs to the technical field of intelligent drug delivery control, and particularly discloses a colon tumor drug delivery method and system based on AI control, and the method comprises the steps: collecting and preprocessing whole genome sequencing, radiomics, clinical pathology and historical drug treatment response data of a patient, extracting tumor image features, and carrying out drug delivery. The method comprises the following steps: screening oxaliplatin response related gene mutation markers by combining Lasso regression with a Cox model, forming feature vectors by t-SNE dimensionality reduction clinical pathological data, training a model through a gradient boosting tree and deep neural network fusion algorithm, taking oxaliplatin response probability as output, and recommending an FOLFOX scheme or an FULV scheme according to a model result. According to the method, precision and individuation of chemotherapy are achieved, unnecessary toxic and side effects are reduced, the life quality and lifetime of a patient are improved, and the problems that in the prior art, dependence on experience, single data dimension, no dynamic adjustment mechanism and poor stability are solved. Therefore, the problems of low response rate of oxaliplatin and obvious side effect are solved.

This invention discloses the application of methylene blue in the preparation of drugs for treating lymphoma, belonging to the field of therapeutic drug technology. This invention creatively discovers that methylene blue can be used as a drug for treating lymphoma, exhibiting cytotoxic effects against human diffuse large B-cell lymphoma cell lines including U2932, TMD8, SUDHL-4, and OCI-LY19, as well as human peripheral T-cell lymphoma cell lines including KARPAS299, SMZ-1, and KHYG-1, and its in vitro activity is superior to first-line chemotherapy drugs. This invention provides an effective option for researching lymphoma treatment strategies and preparing new drugs for treating lymphoma.

The invention relates to the technical field of biology, in particular to application of a PHB2 protein or a coding gene of the PHB2 protein in preparation of a medicine for regulating and controlling adipogenesis. The invention discovers that the PHB2 protein, the encoding gene of the PHB2 protein or the biological material containing the encoding gene can regulate and control the adipogenesis for the first time, and the effect of inhibiting the adipogenesis is achieved by improving the activity of the PHB2 protein or improving the expression quantity of the encoding gene. Therefore, the PHB2 protein and the encoding gene of the PHB2 protein can be used as a target for preparing a medicine for regulating and controlling adipogenesis, a medicine for treating animal obesity and a product for regulating and controlling adipocyte differentiation, and can also be used as a target for screening the medicine for regulating and controlling the adipogenesis. The invention provides a new technical scheme for solving the problem of chicken abdominal fat deposition.

This invention belongs to the field of biomedical technology and discloses the application of olaparib in combination with taquimod in the preparation of anti-tumor metastasis drugs. This invention is the first to discover that olaparib and taquimod, even at low concentrations (i.e., concentrations that do not affect tumor cell proliferation), can effectively inhibit the invasion and metastasis of breast cancer cells, exhibiting high safety. Furthermore, when olaparib and taquimod are used in combination, the inhibitory effect on breast cell invasion and metastasis shows a synergistic enhancement trend, with significantly better efficacy than single-drug therapy, overcoming the limitations of monotherapy. Moreover, the combination of olaparib and taquimod can effectively inhibit lung metastasis of breast cancer, providing a new theoretical basis and medication regimen for anti-metastasis treatment of breast cancer.

The invention relates to application of forsythiaside in treating cerebral arterial thrombosis, and belongs to the technical field of biological medicine. The phillygenin is a small molecule compound extracted from traditional Chinese medicine fructus forsythiae, can be transported into the brain through LILRA5 protein on the surface of peripheral blood mononuclear cells, acts on astrocytes, inhibits combination of PTP1B and FGFR1, enhances phosphorylation of FGFR1, and activates a downstream protective signal channel, so that the neuroprotective effect is achieved. Experiments show that forsythiaside can significantly reduce the volume of cerebral infarction and improve neurological impairment. The invention provides new candidate molecules and mechanism targets for the drug treatment of cerebral arterial thrombosis.

The application provides a temperature-sensitive PAD4 inhibitor-loaded hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines.The temperature-sensitive PAD4 inhibitor-loaded hydrogel comprises a temperature-sensitive hydrogel base and a PAD4 inhibitor loaded in the temperature-sensitive hydrogel base; the components of the temperature-sensitive hydrogel base comprise chitosan and beta-glycerophosphate disodium; and the PAD4 inhibitor has a structure shown in formula 1.The PAD4 inhibitor is loaded in the hydrogel, the PAD4 inhibitor is slowly released through local application, the formation of NETs is inhibited for a long time, the chronic inflammation is reduced, and finally the healing process of a diabetic wound is accelerated.The temperature-sensitive PAD4 inhibitor-loaded hydrogel provided by the application shows a significant therapeutic effect in experiments, and overcomes the limitations of traditional drug treatment to a certain extent.

A system for training medical providers in obesity management and obesity-related comorbidities includes a user device presenting a conversational interface to a medical provider, an application server managing user sessions, a database server storing user data including course completion records and clinical performance audits, and a learning management system server delivering educational modules based on established competencies. An artificial intelligence server processes queries from the medical provider and provides personalized medical advice using a large language model trained on obesity-related medical content including obesity physiology, pharmacotherapy, and patient management. The artificial intelligence server receives outcome information related to patient health metrics following the personalized medical advice and retrains the large language model based on the outcome information. A performance audit system monitors clinical documentation, prescribing patterns, and patient outcomes of the medical provider to ensure ongoing compliance and performance improvements.

The present invention relates to medicaments, treatment methods, kits, and uses for treating cancer in individuals, characterized in that a VEGF signaling inhibitor and a PD-1 / PD-L1 signaling inhibitor are administered in combination, as well as VEGF signaling inhibitors, PD-1 / PD-L1 signaling inhibitors, and combinations thereof.

The invention discloses a medicine for treating arterial venous thrombosis obliterans of lower limbs and a preparation method of the medicine. The problem that an existing treatment means is low in cure rate is solved. The medicine is prepared from 21.85 g to 21.90 g of potassium nitrate, 24.95 g to 25.05 g of alumen, four croton seeds, 6.20 g to 6.30 g of mercury and 0.009 g to 0.011 g of white cast iron. The preparation method comprises the following steps: flatly spreading the raw materials on a heat-resistant container with a condensation cover (with a gap of 2-3cm reserved), heating for 9-11 minutes by soft fire at the temperature of 50-80 DEG C to evaporate water, heating for 19-21 minutes by big fire at the temperature of 120-150 DEG C to sublimate and desublimate the active ingredients, cooling, and filling into capsules. The cure rate of the medicine for treating lower limb arterial thrombosis obliterans is 95%, the cure rate of venous thrombosis obliterans is 90%, the preparation process is simple, the activity of effective components can be reserved, and the medicine is suitable for clinical treatment.

The invention discloses a degradable metal stent with a medicine storage cavity and a manufacturing method of the degradable metal stent, and relates to the technical field of medical instrument manufacturing. The inner-layer bracket and the outer-layer bracket are of hollow structures; the non-hollow parts of the inner-layer stent and the outer-layer stent are consistent in shape and are aligned and attached to each other; medicine storage grooves are distributed in a non-hollow part of the inner-layer bracket; the inner-layer stent and the outer-layer stent are both degradable metal stents. According to the invention, the drug coating on the outer layer of the stent releases the drug for early treatment, and the degradation speed of the outer-layer stent is higher than that of the inner-layer stent, so that the outer-layer stent can be degraded and disappear before the inner-layer stent, the drug storage groove on the inner-layer stent is exposed, and the drug is released again for treatment; therefore, long-time-span drug treatment can be conveniently achieved, and the problem that treatment is not convenient when plaques become large or blood vessels are blocked in the later period of the blood vessels is effectively solved.

The application relates to a compound for improving vascular endothelial cell function, a preparation method and application thereof. The compound is prepared by taking tyrosol, dopamine, substituted cinnamic acid or 5-carboxyl pentyl-triphenyl phosphonium bromide as a starting material, and then performing amidation or esterification reaction with adamantylamine and adamantane acid. The compound has a significant inhibitory effect on the inflammation reaction of endothelial cells induced by palmitate (PA) as an anti-inflammatory molecule, can be used for preparing drugs for hyperlipidemia and related cardiovascular diseases, treating vascular endothelial injury diseases, treating hyperlipidemia, atherosclerosis and related cardiovascular diseases, and has the potential of being developed into innovative drugs for treating hyperlipidemia, atherosclerosis and related cardiovascular diseases with high efficiency and low toxicity.

The invention discloses a lipid-anchored cell-derived vesicle and application thereof, the lipid-anchored cell-derived vesicle is prepared from monoacyl phosphatidylcholine and a cell membrane, and the monoacyl phosphatidylcholine is constructed by taking choline glycerophosphate as a hydrophilic head group and connecting an ester bond with a hydrophobic group. The invention designs a method for enhancing the stability of the cell-derived vesicle by anchoring the cell-derived vesicle with monoacyl phosphatidylcholine, which can prolong the blood circulation half-life period of the drug and improve the delivery effect of the tumor site, thereby enhancing the overall treatment effect of the drug.

The application relates to the technical field of biological medicine, and particularly discloses application of SHP-1 agonist SC-43 in preparation of a medicine for treating esophageal squamous cell carcinoma, a structural formula of the SHP-1 agonist SC-43 is as follows: the medicine has a mechanism of action for treating esophageal squamous cell carcinoma, which includes direct cytotoxicity and / or immune microenvironment regulation; the medicine comprises a therapeutically effective amount of the SHP-1 agonist SC-43 and a pharmaceutically acceptable carrier. The application discloses a new use of the SHP-1 agonist SC-43, and relates to application of SC-43 in preparation of the medicine for treating esophageal squamous cell carcinoma, which provides a brand-new and effective treatment strategy for refractory tumors ESCC.

The invention belongs to the field of medicine treatment, and particularly relates to application of an MASH treatment active ingredient in preparation of a medicine for preventing and / or treating metabolic dysfunction related steatohepatitis, and the MASH treatment active ingredient is used as a pharmacodynamic active ingredient to be used for preparing the medicine for preventing and / or treating the metabolic dysfunction related steatohepatitis. The MASH treatment active component is a compound with a structure shown in a formula 1. Researches show that the formula 1 is innovatively used as an active ingredient, and the formula 1 can be used for preventing and treating MASH and can relieve further progress of MASH.

The present invention relates to a system and method for managing neurological and psychological disorders, with a specific focus on Obsessive-Compulsive Disorder (OCD). The invention integrates pharmacotherapy, Deep Transcranial Magnetic Stimulation (Deep TMS), and Exposure and Response Prevention (ERP) therapy into a unified framework that addresses the chemical, neurological, and behavioural dimensions of OCD. The system utilizes advanced data analysis and machine learning algorithms to dynamically customize interventions based on patient-specific profiles, ensuring optimal therapeutic efficacy and reduced side effects. The System includes real-time data-driven adjustments, high-intensity engagement protocols, remote monitoring for long-term management, and scalable group therapy capabilities. The system also incorporates advanced neuromodulation technologies and compressed ERP techniques to accelerate behavioural restructuring and neural circuit modulation. By leveraging the synergy between these modalities, the invention provides a holistic and versatile solution for improving patient outcomes, ensuring sustained symptom relief and enhanced quality of life.

The present invention relates to a speech-voice evaluation and treatment protocol determination software system for a speech-voice disorder digital therapeutic device of a Parkinson's disease patient and, more specifically, to a speech-voice evaluation and treatment protocol determination software system for a speech-voice disorder digital therapeutic device of a Parkinson's disease patient, which can provide non-pharmacological treatment for a speech-voice disorder. In order to evaluate a speech-voice disorder and provide a user-customized treatment, the present invention may evaluate (diagnose) a speech-voice function of a user for each detailed evaluation item by using a preset automation process for the speech-voice disorder of the user, and provide a treatment protocol to the user for each detailed treatment module on the basis of a result of the evaluation.

The application discloses an indoline compound and a preparation method and application thereof, and belongs to the fields of medicinal chemistry and pharmacotherapy. The compound shown in the formula I, isomers or pharmaceutically acceptable salts thereof have good anti-HBV activity, can effectively inhibit the replication of HBV DNA, can be applied to the preparation of anti-HBV drugs, and have excellent potential application prospect.